Compare Nomura Holdings Inc (NMR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs TG Therapeutics Inc — how do they compare? Nomura Holdings Inc trades at $9.4 (market cap $27.46B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Nomura Holdings Inc is far larger — about 3.3× TG Therapeutics Inc's market cap, and Nomura Holdings Inc pays a 3.45% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NMR | TGTX | |
|---|---|---|
Market Cap | $27.46B | $8.26B |
Sector | Financials | Health |
52-Week High | $10.04 | $59.06 |
52-Week Low | $6.39 | $26.39 |
Dividend Yield | 3.45% | — |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.81, up 4.36% with a bullish technical signal from moving averages. The company reported record annual profit of $340.74 billion for 2025, with revenue growing to $1.66 trillion and profit margin expanding to 20.49%. Recent news highlights strong wholesale revenue growth exceeding 30% and strategic acquisitions in US asset management. The stock trades at a P/E of 12.77, below industry averages, suggesting potential undervaluation.
Outlook remains positive with continued wholesale business momentum and global expansion initiatives. Key risks include integration costs from recent acquisitions and potential market volatility. Analyst consensus shows 33% buy ratings with no sell recommendations, indicating cautious optimism. The combination of reasonable valuation and strong fundamental performance supports potential upside.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
